New study links contraceptive pills and depression
In a global perspective, depression is the leading cause of ill health and disability. More than 264 million people are affected and at least 25 per cent of… read more.
In a global perspective, depression is the leading cause of ill health and disability. More than 264 million people are affected and at least 25 per cent of… read more.
In patients diagnosed with grade 2 IDH-mutant glioma, treatment with investigative vorasidenib has significantly improved progression-free survival. The findings were published on June 5, 2023 in the NEJM/New… read more.
TG Therapeutics announced that the European Commission (EC) has granted approval of Briumvi (ublituximab xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS)… read more.
In an international study co-led by UCLA, scientists have shown that a new targeted therapy drug can extend the amount of time people with a subtype of glioma… read more.
Neurocrine Biosciences, Inc. presented findings from a meta-analysis of three long-term studies evaluating Ingrezza (valbenazine) capsules that demonstrated substantial and sustained improvements in tardive dyskinesia (TD) in adults… read more.
Anxiety and depression are the mental health issues most commonly associated with inflammatory arthritis, and it is well-established that there is a link between mental health issues and… read more.
Ketamine taken in the form of a nasal spray may prove a safe and effective treatment for refractory chronic migraine, suggests a single centre study, published in the… read more.
How do you diagnose and manage depression in adolescents? A new review published in CMAJ (Canadian Medical Association Journal) https://www.cmaj.ca/lookup/doi/10.1503/cmaj.220966 aims to help primary care clinicians address this increasingly common, yet under-detected… read more.
With children more plugged in to social media than ever before, a wave of new image editing apps and filters along with trends related to appearance have parents… read more.
Braeburn announces that the FDA has approved Brixadi (buprenorphine) extended-release injection for subcutaneous use (CIII), a new weekly and monthly medication for moderate to severe opioid use disorder… read more.
Analysis of over 30 years of data has shown the number of cases of low back pain is growing, with modelling suggesting by 2050, 843 million people will… read more.
A new study led by investigators from Mass General Brigham has found that subanesthetic intravenous ketamine was effective and not inferior to electroconvulsive therapy (ECT) for the treatment of non-psychotic,… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.